Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

277
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
277
Integration by Parts: Indefinite Integrals01:26

Integration by Parts: Indefinite Integrals

171
Integration by parts is a fundamental technique in calculus for evaluating integrals involving the product of two functions. It is particularly useful when direct integration is not feasible. The method is based on the product rule for differentiation, which states that the derivative of a product equals the derivative of the first function times the second, plus the first function times the derivative of the second. By integrating this identity and rearranging terms, the integration by parts...
171
Integration by Parts: Definite Integrals01:23

Integration by Parts: Definite Integrals

80
Definite integrals involving the product of two functions over a fixed interval can be evaluated using integration by parts. This method rewrites the integral as the difference of a product evaluated at the endpoints and a remaining definite integral that is often simpler to compute.A representative example is the definite integral of the inverse tangent function. Since there is no direct integration formula for arctan ⁡x, the integrand is rewritten as a product of arctan⁡ x and the...
80
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups

29.9K

Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
29.9K
Characteristics of Practical Op Amps01:16

Characteristics of Practical Op Amps

864
A difference amplifier, a crucial component in numerous electronic devices, ideally amplifies only the difference-mode signal, which is the difference between two input signals. However, in practical circuits, the output voltage depends on both the differential gain and the common-mode gain.
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
864
Theoretical Foundations of Nursing Practice01:30

Theoretical Foundations of Nursing Practice

17.4K
Theories play an essential role in organizing patient care. Theories refer to a proposed or followed belief, policy, or procedure that is the basis for action. Nursing theories are knowledge-based concepts that guide nurses' actions, influence nursing education and practice, and allow nurses to care for their patients.
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
17.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner.

Journal of the advanced practitioner in oncology·2018
Same author

Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2018
Same author

Biosimilars: Beginning a Conversation.

Journal of the advanced practitioner in oncology·2017
Same author

Hypercalcemia of Malignancy.

Journal of the advanced practitioner in oncology·2016
Same author

The Launch of the Advanced Practitioner Society for Hematology and Oncology (APSHO).

Journal of the advanced practitioner in oncology·2014
Same author

Management strategies in pancreatic cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2011

Related Experiment Video

Updated: Feb 3, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner.

Christopher J Campen1

  • 1Greenville Health System Cancer Institute-Pharmacy, Greenville, South Carolina.

Journal of the Advanced Practitioner in Oncology
|October 19, 2018
PubMed
Summary

Biosimilar agents offer significant cost savings in healthcare. Advanced practitioners are key to educating patients and staff for successful oncology integration of these highly similar biologic products.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
A Practical Guide to Phylogenetics for Nonexperts
12:00

A Practical Guide to Phylogenetics for Nonexperts

Published on: February 5, 2014

36.1K

Related Experiment Videos

Last Updated: Feb 3, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
A Practical Guide to Phylogenetics for Nonexperts
12:00

A Practical Guide to Phylogenetics for Nonexperts

Published on: February 5, 2014

36.1K

Area of Science:

  • Biopharmaceutical science
  • Health economics
  • Oncology

Background:

  • Biosimilar agents are highly similar to approved reference biologic products.
  • The Biologics Price Competition and Innovation (BCPI) Act of 2010 established an abbreviated pathway for biosimilar approval in the US.
  • Biosimilars have the potential to reduce healthcare costs for patients and systems.

Purpose of the Study:

  • To describe the chemical and clinical characteristics of biosimilar agents.
  • To review key areas for biosimilar development in oncology.
  • To discuss strategies for implementing biosimilars in clinical practice and educating patients.

Main Methods:

  • Review of the regulatory framework for biosimilar approval.
  • Analysis of factors influencing biosimilar integration into healthcare systems.
  • Discussion of educational strategies for patients and healthcare professionals.

Main Results:

  • Legislation provides a framework for abbreviated biosimilar approval.
  • Successful integration hinges on patient and staff education, with advanced practitioners playing a crucial role.
  • Expanding biosimilar use beyond supportive care presents unique challenges.

Conclusions:

  • Biosimilars represent a significant advancement in biologics, offering cost-effective alternatives.
  • Proactive education and strategic implementation are vital for maximizing biosimilar benefits in oncology.
  • Advanced practitioners are essential leaders in the adoption of biosimilar therapies.